1532 - Expansion of genetic testing for myeloproliferative neoplasms under MBS item 73325

Page last updated: 15 February 2021

Application Detail

Description of Medical Service

Molecular testing for the diagnosis of polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF) can establish the presence or absence of specific mutations known to occur in patients with these disorders. MBS item 73325 currently provides for Janus kinase (JAK2) and myeloproliferative leukaemia (MPL) gene testing in patients with PV or ET. The proposed medical service being requested is the expansion of MBS item 73325 to allow testing for calreticulin (CALR) mutations in patients with PV or ET, and testing for JAK2, MPL and CALR genes in patients with primary myelofibrosis (PMF).

Description of Medical Condition

Myeloproliferative neoplasms (MPNs) are a group of disorders in which bone marrow stem cells grow and reproduce abnormally. PV, ET and PMF are MPN's.

Reason for Application

Amendment to MBS item

Medical Service Type


Previous Application Number


Associated Documentation

Application Form


Consultation Survey

Consultation Survey (PDF 168 KB)
Consultation Survey (Word 70 KB)

PICO Confirmation


Assessment Report


Public Summary Document

Public Summary Document - March 2019 (PDF 945 KB)
Public Summary Document - March 2019 (Word 216 KB)

Public Summary Document - November 2020 (PDF 882 KB)
Public Summary Document - November 2020 (Word 8334 KB)

Meetings for this Application




8 February 2019
8-9 October 2020


28-29 March 2019
26-27 November 2020